Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

Sponsor

Facet Biotech (Industry)

Overall Status

Completed

CT.gov ID

NCT00425347

Collaborator

(none)

Enrollment

Locations

Duration (Months)

4.4

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To identify the MTD of HuLuc63 administered intravenously (IV) for 4 doses.2. To evaluate the safety of HuLuc63 IV given every other week for 4 doses.

Condition or Disease	Intervention/Treatment	Phase
Multiple Myeloma	Drug: HuLuc63	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

35 participants

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma

Study Start Date :

Dec 1, 2006

Actual Primary Completion Date :

Aug 1, 2008

Actual Study Completion Date :

Jul 1, 2009

Outcome Measures

Primary Outcome Measures

Not applicable for this trial. [Not applicable for this trial.]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:

Males or females, age 18 years or older.
Diagnosis of advanced multiple myeloma, after at least 2 prior therapies for MM.
Measurable disease M component in serum (at least 0.5 G/dL) and/or urine (≥0.2 g excreted in a 24-hour collection sample).
Not eligible for stem cell or bone marrow transplant or have refused stem cell or bone marrow transplant or have relapsed after autologous or allogeneic stem cell or bone marrow transplant.
ECOG performance status 0-2 (Appendix E).
ALT or AST ≤3 x ULN.
Total bilirubin ≤2 x ULN (unless related to MM).
Serum creatinine ≤2.0 mg/dL (unless related to MM, then ≤ 3.0 mg/dL).
Must have adequate bone marrow function defined as: Absolute neutrophil count >1,000 cells/mm3; platelets ≥75,000 cells/mm3; and hemoglobin ≥8 g/dL. No platelet transfusion within 72 hours of obtaining screening platelet count.
Serum calcium (corrected for albumin) level within normal range (treatment of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal with treatment).
Signed and dated informed consent.
Use of appropriate contraception where applicable.
Negative pregnancy test within 48 hours prior to first dose in women of childbearing potential.
Must have 2-dimensional echocardiogram or MUGA indicating LVEF ≥ 45% within 30 days prior to first dose of study drug.
Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).

Exclusion Criteria:

Subjects will be ineligible for this study if they meet any one of the following criteria:

Life expectancy of less than 3 months.
Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 5 years.
Plasma cell leukemia (active or prior).
Uncontrolled medical problems such as diabetes mellitus, coronary artery disease, hypertension, unstable angina, arrhythmias, pulmonary, hepatic, and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma (serum creatinine > 2.0 mg/dL).
Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.
Corticosteroid, Velcade® or other proteosome inhibitor, thalidomide, lenalidomide (Revlimid®), or melphalan within 2 weeks of the first dose of HuLuc63; nitrogen mustard agents within 6 weeks of the first dose of HuLuc63.
Investigational drug within 4 weeks or 5 half-lives (whichever is greater) of the first dose of HuLuc63.
Stem cell or bone marrow transplant within 12 weeks prior to the first dose of HuLuc63.
Biological agents including intravenous immune globulin (IVIG) and monoclonal antibodies within 4 weeks of the first dose of HuLuc63.
Neuropathy >Grade 2 (according to the NCI CTCAE v3.0 criteria scale).
Symptomatic orthostatic hypotension.
Evidence of amyloidosis.
Known active infections requiring antibiotics, antivirals, or antifungals.
Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation.
Hypersensitivity to recombinant proteins or excipients in the investigational agent.
Any condition that in the investigator's opinion makes the subject unsuitable for study participation.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Arkansas Cancer Research Center	Little Rock	Arkansas	United States	72205
2	USC/Norris Cancer Hospital	Los Angeles	California	United States	90033
3	Northwestern University Feinberg School of Medicine	Chicago	Illinois	United States	60611
4	Dana-Farber Cancer Institute	Boston	Massachusetts	United States	02115
5	University of Massachusetts Memorial Healthcare- Univ. Campus	Worcester	Massachusetts	United States	01655
6	Wayne State University	Detroit	Michigan	United States	48201
7	Cleveland Clinic	Cleveland	Ohio	United States	44195
8	Fred Hutchinson Cancer Research Center	Seattle	Washington	United States	98109

Sponsors and Collaborators

Facet Biotech

Investigators

Principal Investigator: William Bensinger, MD, Fred Hutchinson Cancer Center
Principal Investigator: Robert Dean, MD, The Cleveland Clinic
Principal Investigator: Frits van Rhee, M.D., Arkansas Cancer Research Center
Principal Investigator: Seema Singhal, M.D., Northwestern University Feinberg School of Medicine
Principal Investigator: Jeffrey A. Zonder, M.D., Wayne State University
Principal Investigator: Samer Al-Homsi, M.D., University of Massachusetts Memorial Healthcare
Principal Investigator: Nikhil Munshi, M.D., Dana-Farber Cancer Institute
Principal Investigator: Ann Mohrbacher, M.D., USC/Norris Cancer Hospital